142 research outputs found
The impact of hearing loss on cognitive decline and risk of progression to mild cognitive impairment in healthy adults
Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice
Type 2 diabetes is a risk factor for Alzheimer's disease (AD). Previously, we have shown that the diabetes drug liraglutide is protective in middle aged and in old APP/PS1 mice. Here, we show that liraglutide has prophylactic properties. When injecting liraglutide once-daily ip. in two months old mice for 8 months, the main hallmarks of AD were much reduced. Memory formation in object recognition and Morris water maze were normalised and synapse loss and the loss of synaptic plasticity was prevented. In addition, amyloid plaque load, including dense core congophilic plaques, was much reduced. Chronic inflammation (activated microglia) was also reduced in the cortex, and neurogenesis was enhanced in the dentate gyrus. The results demonstrate that liraglutide may protect from progressive neurodegeneration that develops in AD. The drug is currently in clinical trials in patients with AD
The Potential of a Stratified Approach to Drug Repurposing in Alzheimerâs Disease
Alzheimerâs disease (AD) is a complex neurodegenerative condition that is characterized by the build-up of amyloid-beta plaques and neurofibrillary tangles. While multiple theories explaining the aetiology of the disease have been suggested, the underlying cause of the disease is still unknown. Despite this, several modifiable and non-modifiable factors that increase the risk of developing AD have been identified. To date, only eight AD drugs have ever gained regulatory approval, including six symptomatic and two disease-modifying drugs. However, not all are available in all countries and high costs associated with new disease-modifying biologics prevent large proportions of the patient population from accessing them. With the current patient population expected to triple by 2050, it is imperative that new, effective, and affordable drugs become available to patients. Traditional drug development strategies have a 99% failure rate in AD, which is far higher than in other disease areas. Even when a drug does reach the market, additional barriers such as high cost and lack of accessibility prevent patients from benefiting from them. In this review, we discuss how a stratified medicine drug repurposing approach may address some of the limitations and barriers that traditional strategies face in relation to drug development in AD. We believe that novel, stratified drug repurposing studies may expedite the discovery of alternative, effective, and more affordable treatment options for a rapidly expanding patient population in comparison with traditional drug development methods
Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals
Additional file 5. Standardised features
Distinguishing normal brain aging from the development of Alzheimer's disease: inflammation, insulin signaling and cognition
As populations age, prevalence of Alzheimer's disease (AD) is rising. Over 100 years of research has provided valuable insights into the pathophysiology of the disease, for which age is the principal risk factor. However, in recent years, a multitude of clinical trial failures has led to pharmaceutical corporations becoming more and more unwilling to support drug development in AD. It is possible that dependence on the amyloid cascade hypothesis as a guide for preclinical research and drug discovery is part of the problem. Accumulating evidence suggests that amyloid plaques and tau tangles are evident in non-demented individuals and that reducing or clearing these lesions does not always result in clinical improvement. Normal aging is associated with pathologies and cognitive decline that are similar to those observed in AD, making differentiation of AD-related cognitive decline and neuropathology challenging. In this mini-review, we discuss the difficulties with discerning normal, age-related cognitive decline with that related to AD. We also discuss some neuropathological features of AD and aging, including amyloid and tau pathology, synapse loss, inflammation and insulin signaling in the brain, with a view to highlighting cognitive or neuropathological markers that distinguish AD from normal aging. It is hoped that this review will help to bolster future preclinical research and support the development of clinical tools and therapeutics for AD
The impact of hearing impairment and hearing aid use on progression to mild cognitive impairment in cognitively healthy adults: An observational cohort study
INTRODUCTION: We assessed the association of selfâreported hearing impairment and hearing aid use with cognitive decline and progression to mild cognitive impairment (MCI). METHODS: We used a large referralâbased cohort of 4358 participants obtained from the National Alzheimer's Coordinating Center. The standard covariateâadjusted Cox proportional hazards model, the marginal structural Cox model with inverse probability weighting, standardized KaplanâMeier curves, and linear mixedâeffects models were applied to test the hypotheses. RESULTS: Hearing impairment was associated with increased risk of MCI (standardized hazard ratio [HR] 2.58, 95% confidence interval [CI: 1.73 to 3.84], PÂ =Â .004) and an accelerated rate of cognitive decline (PÂ <Â .001). Hearing aid users were less likely to develop MCI than hearingâimpaired individuals who did not use a hearing aid (HR 0.47, 95% CI [0.29 to 0.74], PÂ =Â .001). No difference in risk of MCI was observed between individuals with normal hearing and hearingâimpaired adults using hearing aids (HRâ0.86, 95% CI [0.56 to 1.34], PÂ =Â .51). DISCUSSION: Use of hearing aids may help mitigate cognitive decline associated with hearing loss
The impact of hearing loss and sensory intervention on the risk of progression to dementia in mild cognitive impairment cases
- âŠ